Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Tripeptides – e.g. – tripeptide thyroliberin – etc.
Patent
1997-09-03
2000-08-15
Tsang, Cecilia J.
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Tripeptides, e.g., tripeptide thyroliberin , etc.
530330, 514 18, 514 19, A61K 3806
Patent
active
061038709
ABSTRACT:
The present invention contemplates a peptide that inhibits the binding between the VLA-4 receptor expressed on inflammatory leukocytes and the fibronectin CS-1 peptide expressed on endothelial cells that are involved in immunoinflammatory disease states. Pharmaceutical compositions containing a contemplated peptide and processes for treating immunoinflammatory conditions using a binding-inhibitory peptide are also disclosed.
REFERENCES:
patent: 4564616 (1986-01-01), Jones et al.
patent: 4822606 (1989-04-01), Snyderman et al.
patent: 5294511 (1994-03-01), Furcht et al.
patent: 5294551 (1994-03-01), Furcht et al.
patent: 5340802 (1994-08-01), Shiosaki et al.
patent: 5387504 (1995-02-01), Mumford
Galleyrand, Peptides 519, 1992.
Komoriya, Akira et al., "The Minimal Essential Sequence for a Major Cell Type-specific Adhesion Site (CS1) within the Alternatively Splice Type III Connecting Segment Domain of Fibronectin is Leucine-Aspartic Acid-Valine." J. Biol. Chem. 266:15075-15079 (1991).
Elices, Mariano "The Integrin .alpha..sub.4 .beta..sub.1 (VLA-4) as a Therapeutic Target." Cell Adhesion and Human Disease. Wiley, Chichester (Ciba Foundation Symposium 189) pp. 79-90 (1995).
Nowlin, Dawn M., "A Novel Cyclic Pentapeptide Inhibits .alpha.4.beta.1 and .alpha.5.beta.1 Integrin-mediated Cell Adhesion." J. Biol. Chem. 268:20352-20359 (1993).
Mousa, Shaker A. et al., "Antiplatelet Efficacy and Specificity of DMP728, a Novel Platelet GP11b/IIIa Receptor Antagonist." Clin. Pharm. 83:374-382 (1993).
Pfaff, Martin et al., "Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by .alpha.V.beta.3, .alpha.5.beta.1 Integrins." J. Biol. Chem. 269:20233-20238 (1994).
Iorio et al., "Synthesis, Stereo chemistry, and Biological Activity of the 1-(1-Phenyl-2-methylcyclohexyl)piperidines and the 1-(1-Phenyl-4-methylcyclohexyl)piperidines. Absolute Configuration of the Potent trans-(--)-1-(1-Phenyl-2-methylcyclohexyl)piperidine," J.Med. Chem., 34:2615-2623 (1991).
Esser, F. and Roos, O. "N-terminal Cyclization of Peptides with N,N'-Carbonyldiimidazole or N,N'-Thiocarbonyldiimidaxole"Angew. Chem. Int. Ed. Engl. 17(6):467-468 (1978).
Komoriya et al., "minimal essential sequence for a Major cell Type specific adhesion site (CS1) within the alternatively sliced type III connecting segment domain of fibronectin is leucine-aspartic acid Valine, " J. Biol. Chem. 266:15075-15079 (1991).
Arrhenius Thomas S.
Elices Mariano J.
Gaeta Federico C. A.
Cytel Corporation
Lukton David
Tsang Cecilia J.
LandOfFree
CS-1 peptidomimetic, compositions and methods of using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CS-1 peptidomimetic, compositions and methods of using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CS-1 peptidomimetic, compositions and methods of using the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2008113